Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States

Hepatology

Volumn 53, Issue 3, 2011, Pages 737-745

  Stepanova, Maria ^a,d   Kanwal, Fasiha ^b   El Serag, Hashem B ^c   Younossi, Zobair M ^a,d  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; VIRUS ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GOVERNMENT; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH SURVEY; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH; PUBLIC HEALTH INSURANCE; UNITED STATES; VIRUS DETECTION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; INTERFERON ALFA-2A; MALE; MEDICAID; MEDICALLY UNINSURED; MIDDLE AGED; NUTRITION SURVEYS; POLYETHYLENE GLYCOLS; RIBAVIRIN; UNITED STATES;

EID: 79952233518     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24131     Document Type: Article

References (22)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441.
2. Tan J, Lok AS. Update on viral hepatitis: 2006. Curr Opin Gastroenterol 2007; 23: 263-267.
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
4. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006; 10: 697-715.
5. Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006; 121: 710-719.
6. Younossi ZM, Singer ME, McHutchison JG, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. HEPATOLOGY 1999; 30: 1318-1324.
7. Birerdinc A, Younossi ZM. Emerging therapies for hepatitis C virus. Expert Opin Emerg Drugs 2010; doi:10.1517/14728214.2010.502527.
8. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
9. McHutchison JG, Bacon BR, Owens GS. Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care 2007; 13(Suppl. 12): S327-S336.
10. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. HEPATOLOGY 2007; 45: 806-816.
11. Bacon BR, McHutchison JG. Into the light: strategies for battling hepatitis C. Am J Manag Care 2007; 13(Suppl. 12): S319-S326.
12. Gentile I, Carleo MA, Borgia F, Castaldo G, Borgia G. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010; 19: 151-159.
13. Fowell AJ, Nash KL. Telaprevir: a new hope in the treatment of chronic hepatitis C? Adv Ther 2010; 27: 512-522.
14. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. HEPATOLOGY 2009; 50: 1750-1755.
15. Nease DEJr, Maloin JM. Depression screening: a practical strategy. J Fam Pract 2003; 52: 118-124.
16. National Center for Health Statistics, Centers for Disease Control and Prevention. Analytic and reporting guidelines: The National Health and Nutrition Examination Survey (NHANES). Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention; 2005.
17. U.S. Census Bureau. Percent of people 25 years and over who have completed a bachelor's degree. Published 2003. Accessed August 10, 2010.
18. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. HEPATOLOGY 2007; 46: 912-921.
19. Stepanova M, Rafiq N, Younossi Z. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010; 59: 1410-1415.
20. Ong JP, Collantes R, Pitts A, Martin L, Sheridan M, Younossi ZM. High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol 2005; 39: 826-830.
21. Kanwal F, Hoang T, Spiegel BM, Goetz M, Gralnek IM, Dominitz JA, et al. Quality of care in chronic hepatitis C virus (HCV) infection. In: Proceedings of the AASLD Liver Meeting (October 27-31, 2006; Boston, MA, USA). Abstract 1296.
22. Kramer JR, Kanwal F, Mei M, El-Serag H. HCV treatment and SVR: gaps in the face of achieving effectiveness in practice. In: Proceedings of Digestive Disease Week (May 2-5, 2010; New Orleans, LA, USA). Abstract 709.